Aion Therapeutic Inc
CNSX:AION
Aion Therapeutic Inc
Research & Development
Aion Therapeutic Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Aion Therapeutic Inc
CNSX:AION
|
Research & Development
CA$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
High Tide Inc
XTSX:HITI
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Canopy Growth Corp
TSX:WEED
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Aurora Cannabis Inc
TSX:ACB
|
Research & Development
-CA$3.8m
|
CAGR 3-Years
22%
|
CAGR 5-Years
27%
|
CAGR 10-Years
-22%
|
|
|
Sundial Growers Inc
NASDAQ:SNDL
|
Research & Development
-CA$478k
|
CAGR 3-Years
44%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Research & Development
-$4.4m
|
CAGR 3-Years
30%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
Aion Therapeutic Inc
Glance View
Aion Therapeutic, Inc. is an emerging international pharmaceutical company, which focuses on the healing powers of medical cannabis and medicinal mushroom compounds. The company is headquartered in Toronto, Ontario. The company went IPO on 2019-02-21. The firm is focused on the development of combinatorial pharmaceuticals, nutraceuticals and cosmeceuticals utilizing compounds from cannabis (cannabinoids), psychedelic mushrooms (psilocybin), fungi (edible mushroom), natural psychedelic formulations (Ayahuasca) and other medicinal plants for discovery.
See Also
What is Aion Therapeutic Inc's Research & Development?
Research & Development
0
CAD
Based on the financial report for Apr 30, 2023, Aion Therapeutic Inc's Research & Development amounts to 0 CAD.